Zobrazeno 1 - 10
of 501
pro vyhledávání: ''
Publikováno v:
Breast Disease. 40:S33-S37
BACKGROUND: Increased plasma aldehyde dehydrogenase 1 (ALDH1) levels have been proposed to predict cancer chemoresistance. However, studies have reported inconsistent results, depending on the type of cancer cells used. OBJECTIVE: This study aimed to
Autor:
Marc De Man, Pascal Pierre, Erik Vanderstraeten, Ghislain Houbiers, Lionel D'Hondt, Jacques Van Der Auwera, Hassan Rezaei Kalantari, Amélie Deleporte, Ahmad Awada, Lieveke Ameye, Alain Hendlisz, Thierry Delaunoit, Stéphanie Laurent, Francesco Sclafani, Bjorn Ghillemijn, Marylene Clausse, Marianne Paesmans, Angelique Covas, Marc Van den Eynde, Frédéric Forget, Philippe Vergauwe, Stéphane Holbrechts
Publikováno v:
Cancer medicine, Vol. 10, no. 13, p. 4366-4374 (2021)
Cancer Medicine, Vol 10, Iss 13, Pp 4366-4374 (2021)
Cancer Medicine
Cancer Medicine, Vol 10, Iss 13, Pp 4366-4374 (2021)
Cancer Medicine
Background While docetaxel/cisplatin/5‐fluorouracil (DCF) outperforms CF in first‐line gastric adenocarcinoma, toxicity remains an issue. Methods This multicenter phase II trial randomized chemonaïve metastatic gastric adenocarcinoma patients to
Autor:
Alessandro Paniccia, Derek Barclay, Yoram Vodovotz, Jacob C. Hodges, Michael T. Lotze, Pranav Murthy, Amer H. Zureikat, Brian A. Boone, Randall E. Brand, Ruben Zamora, Kenneth K. Lee, Asmita Chopra, Richard L. Simmons
Publikováno v:
J Immunother
Despite its increased application in pancreatic ductal adenocarcinoma (PDAC), complete response to neoadjuvant therapy (NAT) is rare. Given the critical role of host immunity in regulating cancer, we sought to correlate baseline inflammatory profiles
Autor:
Cecilia Becattini, Giancarlo Agnelli, Melina Verso, Rupert Bauersachs, Menno V. Huisman, Andrés Muñoz, Mario Mandalà, Giorgio Vescovo
Publikováno v:
European Journal of Cancer, 148, 371-381. ELSEVIER SCI LTD
Background: Whether concomitant administration of anticancer agents influences the efficacy and safety of oral anticoagulants in patients treated for cancer-associated venous thromboembolism (VTE) is undefined. The pharmacological interaction between
Autor:
Aileen Deng, Jordan M. Winter, Charles J. Yeo, Chun Wang, Atrayee Basu Mallick, Steven J. Cohen, James Posey
Publikováno v:
European Journal of Cancer. 147:17-28
To compare overall survival (OS) in patients who underwent surgery for early-stage pancreatic adenocarcinoma (rPca) based on sequence (NAT, neoadjuvant therapy and/or AT, adjuvant therapy) and type (SA, single-agent or MA, multi-agent) of chemotherap
Publikováno v:
International Journal of Oncology
Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non‑Hodgkin lymphoma that is unique and different from systemic diffuse large B‑cell lymphomas. The median age at diagnosis of PCNSL is 65 years and its incidence is
Autor:
Bella Pajares, Sofia Ruiz-Medina, Enrique Saez, Antonia Márquez, Laura Galvez, Begoña Jimenez, Ana Godoy, Pablo Rodriguez-Brazzarola, Maria E. Dominguez-Recio, Francisco Carabantes, Alfonso Sánchez-Muñoz, María José Bermejo, Irene López, José M. Jerez, Tamara Diaz-Redondo, Ester Villar, Héctor Mesa, Leo Franco, Nuria Ribelles, Emilio Alba
Publikováno v:
European Journal of Cancer. 144:224-231
Background CDK4/6 inhibitors plus endocrine therapies are the current standard of care in the first-line treatment of HR+/HER2-negative metastatic breast cancer, but there are no well-established clinical or molecular predictive factors for patient r
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Several studies have evaluated the role of delayed initiation of adjuvant chemotherapy (AC) in breast cancer (BC), but the results have remained controversial and an optimal time has not been defined. Our aim was to determine the effect of ti
Autor:
Anke Bergmann, Marcelo Adeodato Bello, Luiz Claudio Santos Thuler, Isabella Cristina Santos Soares
Publikováno v:
Breast Cancer Research and Treatment. 187:547-555
Different tumor-related factors have been proposed to assess the risk of disease progression and death in women undergoing neoadjuvant breast cancer chemotherapy. Recently, besides the classical pre-treatment clinical stage (CS) and post-treatment pa
Autor:
Lynda Wyld, Richard Simcock, Jacqui Gath, Alan Brennan, Deirdre Revell, Maria Burton, Riccardo A. Audisio, Jay Naik, Malcolm W.R. Reed, Kwok L. Cheung, Geoffrey Holmes, Charlene Martin, Annaliza Todd, Matthew Hatton, Tim Chater, Kirsty Pemberton, Stephen J Walters, Chris Holcombe, Matthew C Winter, Margot Gosney, Thompson G. Robinson, Kate Lifford, Adrian Edwards, A. Ring, Anne Shrestha, Kieran Horgan, Sue Ward, Juliet Wright, Alastair M. Thompson, Karen Collins, Rishi Parmeshwar, Nicolò Matteo Luca Battisti, Esther Herbert, Jenna Morgan, Age Gap Tmg, Tracey Green, Mike Bradburn
Publikováno v:
European Journal of Cancer
Introduction Older patients with early breast cancer (EBC) derive modest survival benefit from chemotherapy but have increased toxicity risk. Data on the impact of chemotherapy for EBC on quality of life in older patients are limited, but this is a k